Topical antibiotics for preventing surgical site infection in wounds healing by primary intention (Protocol) by Heal, Clare F. et al.
Topical antibiotics for preventing surgical site infection in
wounds healing by primary intention (Protocol)
Heal CF, van Driel ML, Lepper PD, Banks JL
This is a reprint of a Cochrane protocol, prepared and maintained by The Cochrane Collaboration and published in The Cochrane
Library 2014, Issue 12
http://www.thecochranelibrary.com
Topical antibiotics for preventing surgical site infection in wounds healing by primary intention (Protocol)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
11APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
14DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
14SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iTopical antibiotics for preventing surgical site infection in wounds healing by primary intention (Protocol)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Protocol]
Topical antibiotics for preventing surgical site infection in
wounds healing by primary intention
Clare F Heal1, Mieke L van Driel2, Phoebe D Lepper3, Jennifer L Banks3
1General Practice and Rural Medicine, James Cook University, Mackay, Australia. 2Discipline of General Practice, School of Medicine,
The University of Queensland, Brisbane, Australia. 3School of Medicine and Dentistry, James Cook University, Mackay, Australia
Contact address: Clare F Heal, General Practice and Rural Medicine, James Cook University, Mackay Base Hospital, Bridge Road,
Mackay, Queensland, 4740, Australia. clare.heal@jcu.edu.au.
Editorial group: Cochrane Wounds Group.
Publication status and date: New, published in Issue 12, 2014.
Citation: Heal CF, van Driel ML, Lepper PD, Banks JL. Topical antibiotics for preventing surgical site infection in wounds healing by
primary intention.CochraneDatabase of Systematic Reviews 2014, Issue 12. Art.No.:CD011426.DOI: 10.1002/14651858.CD011426.
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To determine if the application of topical antibiotics to wounds healing by primary intention reduces the incidence of surgical site
infection.
B A C K G R O U N D
Description of the condition
Many surgical procedures are conducted each year. The majority
of these procedures result in wounds that heal by primary inten-
tion, which means that the wound edges are approximated us-
ing sutures, staples, clips or glue. In wounds healing by secondary
intention, the edges are not approximated and the wound heals
by granulation, re-epithelialisation and contraction. Most wounds
heal without complications but surgical site infections can occur
after surgery in the site where the surgery took place. Most wound
infections are caused by contamination during surgery with the
patient’s ownmicro-organisms (Kulayalat 2007). They may be su-
perficial and self-limiting, involving the skin only, or they may be
deeper and life-threatening. Surgical site infection is classified by
the Centers for Disease Control (CDC) as superficial incisional,
deep incisional and organ/space infections (CDC 2014;Mangram
1999).
Surgical site infections account for up to 20 per cent of all of
healthcare-associated infections (Magill 2014). At least five per
cent of patients who have a surgical procedure will go on to de-
velop a surgical site infection, highlighting the importance of good
prevention, detection and management (NICE 2008). Superficial
surgical site infections can delay healing, impair cosmetic outcome
and potentially cause other morbidity, such as deeper infections,
as well as potentially increasing costs, and the consumption of
healthcare resources (Bratzler 2004).
In order to understand surgical site infection, it is first important to
understand the classification of surgical wounds. Surgical wounds
are traditionally classified into different categories, and infection
rates vary by category. This classification is important in order to
predict postoperative infection rates and thus aid the decision to
prescribe postoperative antibiotics, whether oral or topical (Table
1).
• Clean (class 1): Noninfective operative wounds in which no
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inflammation is encountered, with no involvement of
respiratory, alimentary, genitourinary tract and oropharyngeal
cavity. Additionally, these wounds must be the result of elective
procedures, closed by primary intention and drained with closed
drainage system if required.
• Clean/contaminated (class 2): Operative wounds in which
either the respiratory, alimentary, or genitourinary tract is
entered under controlled conditions and with only minor
contamination. This category specifically includes wounds as a
result of operations involving the biliary tract, appendix, and
oropharynx, provided no evidence of infection or a major break
in sterile technique is encountered.
• Contaminated (class 3): Fresh, accidental wounds, resulting
from operations with major breaks in sterile technique or gross
spillage from the gastrointestinal tract, and incisions in which
acute, nonpurulent inflammation is encountered. This category
includes traumatic lacerations.
• Dirty (class 4): Old traumatic wounds with retained
devitalised tissue and those that involve existing clinical infection
or perforated viscera. Organisms causing postoperative infection
are likely to be present in the operative field before the operation.
In a general surgical setting the acceptable rate of infection fol-
lowing clean surgery (class 1) is less than 5% (Cruse 1980; Culver
1991; Mangram 1999). In contrast, clean contaminated wounds
(class 2) have a risk of infection of less than 10%. Therefore, in
a general surgical setting, oral antibiotic prophylaxis of surgical
wounds is usually considered optional for clean procedures, and
reserved for certain at risk patients or high risk procedures (Bratzler
2004). If guidelines for prophylaxis after general surgery are ex-
trapolated to a dermatological surgery setting, thenmost dermato-
logical procedures, which are considered to be class 1 clean surgery,
should not require prophylaxis, and most guidelines reflect this
(Maragh 2005; Messingham 2005; Wright 2008). However, as
in general surgery, even within cohorts with a low overall risk of
infection, some procedures may be at higher risk and infection
rates may be greater than 5% in these high risk groups. Although
limited guidelines exist for the use of oral antibiotics as infection
prophylaxis, there are no guidelines for the use of topical antibi-
otics after general and dermatological surgery.
There is no universal agreement on the definition of wound infec-
tion. A systematic review identified 41 different definitions, and
13 grading scales for surgical site infections, the majority of which
had not been validated (Bruce 2001). The most widely accepted
description for dermatologic surgical site infection, however, is
based on the 1992USCDCclassification, in which infectionmust
occur within 30 days of surgery and involve skin or deep tissue at
the incision site (Mangram 1999).
In addition, one of the following must apply:
1. purulent discharge from the incisional wound;
2. organisms are isolated on culture of aseptically obtained
wound fluid or tissue;
3. one or more of the following is present: pain, tenderness,
localised swelling, redness, heat, or the surgeon has deliberately
re-opened wound (unless culture of the incision is negative);
4. the treating doctor diagnoses a superficial incisional surgical
site infection. Stitch abscesses are not defined as infection.
Although this definition has limitations, it is the most widely im-
plemented standard definition of wound infection, and is the clos-
est to a gold standard available. Even when using guidelines, the
diagnosis of infection is still subjective and there may be inter- and
intra-observer variation.
Description of the intervention
Themost commonmethodof application of topical antibiotic is in
the form of an ointment. Other possible delivery methods include
cream, lotion, solution, gel, tincture, foam, paste, powder, and
impregnated dressings. An ointment base classically contains 80%
oil and 20% water, and therefore is more occlusive and will drive
themedication into the skinmore rapidly than a solution or cream
base; thus ointments are an optimal delivery method for topical
antibiotics. The only data available on the frequency of topical
antibiotic use on wounds is a survey of plastic surgeons in the UK
which revealed that 66% used chloramphenicol eye ointment in
their practice, mainly as prophylaxis against infection (Erel 1999).
Other uses for antibiotic ointment include the treatment of secon-
darily infected wounds (Leyden 1987), otitis externa, treatment of
secondarily infected eczema and the treatment of impetigo (AEG
2010). Antibiotic ointments may also have a role in accelerating
wound healing in both acute and chronic situations (Berger 2000;
Eaglstein 1980; Geronemus 1979). Adverse effects may include
allergic contact dermatitis (Blondeel 1978; Leyden 1979; Marks
1998), anaphylaxis (Saryan 1998), and the theoretical possibility
of antibiotic resistance (Bradley 1995; Fukuda 2002;Miller 1996).
There are several different types of antibiotic ointments used in
clinical practice, and the preferred choice varies per country (Table
2). The most frequently used are Chloromycetin, Neosporin and
Bactroban. Chloromycetin ointment consists of 10 mg/g of chlo-
ramphenicol, in plastibase 30W and liquid paraffin (Pfizer 2014).
Neosporin ointment is also known as triple antibiotic ointment in
the USA. Each gram of Neosporin ointment contains polymixin B
sulfate 5000 units, neomycin sulfate 5 mg and bacitracin zinc 400
units in a paraffin ointment base. Bactroban ointment contains
mupirocin, a naturally occurring antibiotic. Many of these topical
antibiotic agents contain antibiotics that are not recommended
for systemic use due to serious adverse effects. The risk of serious
effects is considered low with topical use, thus they are safe for use
in this form (Kasten 1999).
Neosporin ointment has been available over-the-counter in the
USA since the 1970s, while it has been confined to a prescription
medication in Australia. It ceased to be available in Australia in
October 2006, because of non availability of an ingredient.
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How the intervention might work
The role of topical antibiotics is to reduce the microbial contam-
inant exposure following the surgical procedure. A surgeon may
choose to use a topical antibiotic on a wound by considering the
likelihood of infection and weighing up the risks and benefits of
treatment. There is a lack of evidence in the literature regarding
the efficacy of antibiotic ointment in preventing wound infection.
Topical antibiotics have a number of mechanisms of action. Chlo-
ramphenicol is a bacteriostatic broad spectrum antibiotic that ex-
erts an effect by inhibiting protein synthesis of the bacteria and
interfering with transfer of activated amino acids to ribosomes.
Neomycin has moderate gram-negative action through inhibition
of protein synthesis. Mupirocin is active against gram-positive
aerobic bacteria by inhibiting bacterial protein synthesis (HCN
2014). Antibiotics differ from antiseptics as they selectively target
specific organisms, whereas antiseptics non selectively destroy or
inhibit the growth of organisms (McDonnell 1999).
Why it is important to do this review
The question of whether topical antibiotics are useful in the pre-
vention of infections in wounds healing by primary intention is
particularly relevant in primary care. Rationalising the use of an-
tibiotics is important to minimise the impact on antibiotic resis-
tance in the community. Despite the theoretical risk of antibi-
otic resistance, only mupirocin has been shown to contribute to
an emerging resistance pattern when used in vitro (Bradley 1995;
Miller 1996). The evidence for use of topical antibiotics is con-
flicting and therefore a systematic review of trials will be impor-
tant to guide clinical practice. In some countries, such as the USA,
topical antibiotics are available over-the-counter, whereas in others
they are only available when prescribed by a doctor. The efficacy
of this treatment is therefore important to consumers as well as
health practitioners. Better information on its efficacy could assist
in rationalising use and contribute to controlling development of
antibiotic resistance in the community.
O B J E C T I V E S
To determine if the application of topical antibiotics to wounds
healing by primary intention reduces the incidence of surgical site
infection.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include trials reported as randomised controlled trials
(RCTs), or quasi-RCTs with a parallel group design. We will in-
clude trials published as abstracts if sufficient data are available.We
will also include unpublished RCTs if sufficient data are available.
We will accept trials with paired designs (one wound treated with
topical antibiotic, and the other treated without topical antibiotic,
at different sites in the same patient).
Types of participants
We will include:
• people of any age, gender or country of origin who have
undergone surgical procedures where healing of the surgical
wound was planned by primary intention, i.e. where wounds
have edges approximated with sutures, staples, clips or glue;
• any surgical setting, including dermatology outpatients or
inpatients, emergency department, general surgery and primary
care;
• all wound classes; and
• mixed populations (if the data allows the results from the
relevant population to be extracted).
We will exclude:
• studies including people with wounds that are already
infected (secondarily infected wounds), i.e. we will not include
antibiotics for treating rather than preventing wound infection;
• wounds healing by secondary intention; and
• instances where there has been antibiotic irrigation or
washout of wounds, subcutaneous infiltration of the antibiotic,
or any topical treatment applied prior to closure by primary
intention.
Types of interventions
The intervention will be topical antibiotics. This will include oint-
ment, cream, lotion, solution, gel, tincture, foam, paste, powder,
and impregnated dressings. We will not include silver or antisep-
tics in our definition of topical antibiotics. The topical antibiotic
must be applied after the wound is closed by primary intention,
therefore we will not include antibiotic irrigation or washouts,
subcutaneous infiltration of the antibiotic or any topical treatment
applied prior to closure by primary intention. We will not include
antibiotic-coated sutures. We will exclude patients on concomi-
tant systemic antibiotics. We will include single application post-
operatively, or multiple applications in the postoperative period.
We will record dosage of antibiotic if this information is available.
The topical antibiotic may be applied with or without a dressing.
The comparison group will be placebo - which might contain the
vehicle of the topical antibiotic - oral antibiotic, alternative topical
antibiotic, topical antiseptic or no treatment.We will not consider
the comparator groups to be homogenous for the purposes of data
synthesis.
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Types of outcome measures
We will not consider outcomes in eligibility criteria. We will con-
sider secondary outcomes with and without validated scales.
Primary outcomes
• Superficial surgical site infection, as defined by the CDC
definition of surgical site infection. In this definition infection
must occur within 30 days of the procedure, therefore this time
point will be used as a cut-off for this primary outcome measure.
We will also accept the trial authors’ definitions of infection.
• Proportion of patients with any adverse effect within 30
days of the procedure. Adverse effects will be allergic contact
dermatitis, anaphylaxis, or infections with patterns of antibiotic
resistance.
Secondary outcomes
• Wound healing: time-to-healing or proportion of wounds
healed at the end of the trial.
• Patient satisfaction measured within six months of the
procedure.
• Health-related quality of life at 30 days and three months.
• Financial cost for each infection prevented (number needed
to treat) This calculation will be made by using the NNT to
calculate the financial cost of prescribing topical prophylactic
antibiotics to a number of patients in order to prevent a single
wound infection.
Search methods for identification of studies
Electronic searches
Wewill search the following electronic databases to identify reports
of relevant RCTs:
• Cochrane Wounds Group Specialised Register;
• The Cochrane Central Registrar of controlled trials
(CENTRAL) (The Cochrane Library, latest Issue);
• OvidMEDLINE (1946 to present);
• OvidMEDLINE (In-Process & Other Non-Indexed
Citations, present);
• Ovid EMBASE (1974 to present );
• EBSCO CINAHL (1982 to present).
We will use the following provisional search strategy in the
Cochrane Central Register of Controlled Trials (CENTRAL):
#1 MeSH descriptor: [Antibiotic Prophylaxis] this term only
#2 MeSH descriptor: [Anti-Bacterial Agents] explode all trees
#3 MeSH descriptor: [Ointments] this term only
#4 MeSH descriptor: [Skin Cream] this term only
#5 MeSH descriptor: [Administration, Topical] explode all trees
#6 #1 or #2
#7 #5 and #6
#8 (topical near/5 antibiotic*):ti,ab,kw
#9 (mupirocin or bactroban or bacitracin or “polymixin B” or
neomycin or erythromycin or chloramphenicol or chlormycetin
or chlorsig or neosporin):ti,ab,kw
#10 (antibiotic* near/5 (foam* or tincture* or gel or gels or solu-
tion* or lotion* or cream*)):ti,ab,kw
#11 (antibiotic* near/5 (powder* or liquid* or drop* or spray* or
paste* or ointment*)):ti,ab,kw
#12 ((antibiotic* or impregnat*) near/5 dressing*):ti,ab,kw
#13 #3 or #4 or #7 or #8 or #9 or #10 or #11 or #12
#14 MeSH descriptor: [Surgical Wound Infection] explode all
trees
#15 MeSH descriptor: [Surgical Wound Dehiscence] this term
only
#16 (surg* near/5 infect*):ti,ab,kw
#17 (surg* near/5 wound*):ti,ab,kw
#18 (surg* near/5 site*):ti,ab,kw
#19 (surg* near/5 incision*):ti,ab,kw
#20 (surg* near/5 dehisc*):ti,ab,kw
#21 (wound* near/5 dehisc*):ti,ab,kw
#22 (wound* near/5 infect*):ti,ab,kw
#23 (wound* near/5 disrupt*):ti,ab,kw
#24 wound next complication*:ti,ab,kw
#25 #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #
22 or #23 or #24
#26 #13 and #25
Wewill adapt this strategy to searchOvidMEDLINEAppendix 1,
Ovid EMBASE Appendix 2 and EBSCO CINAHL Appendix 3.
We will combine the Ovid MEDLINE search with the Cochrane
Highly Sensitive Search Strategy for identifying randomised tri-
als in MEDLINE: sensitivity- and precision-maximising version
(2008 revision) (Lefebvre 2011). We will combine the EM-
BASE search with the Ovid EMBASE filter developed by the UK
Cochrane Centre (Lefebvre 2011).We will combine theCINAHL
searches with the trial filters developed by the Scottish Intercolle-
giate Guidelines Network SIGN 2011). We will not restrict stud-
ies with respect to language, date of publication or study setting.
We will search the following clinical trials registries:
• ClinicalTrials.gov (http://www.clinicaltrials.gov/);
• WHO International Clinical Trials Registry Platform (http:
//apps.who.int/trialsearch/Default.aspx);
• EU Clinical Trials Register (https://
www.clinicaltrialsregister.eu/).
Searching other resources
We will search the bibliographies of all retrieved and relevant pub-
lications identified by these strategies for additional eligible trials.
While we will not perform handsearches for this review, they are
conducted by the CochraneWounds Group in order to inform the
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Wounds Group Specialised Register, which we will search.We will
contact manufacturers and pharmaceutical companies regarding
studies for inclusion.
Data collection and analysis
We will follow guidelines given by the Cochrane Handbook for
Systematic Reviews of Interventions (Deeks 2011) and theCochrane
Wounds Group.
Selection of studies
Two review authors (CH and PL) will independently screen the
studies identified by the literature search. These review authors
will analyse the titles and abstracts of all citations found through
the search strategy described above. They will obtain a copy of the
full article for each citation reporting a potentially eligible trial.
Independently, the two review authors will apply the eligibility
criteria; any discrepancies will be resolved by consensus discussion
with the third review author (MVD). Where necessary and possi-
ble, additional information will be sought from the principal in-
vestigator of the trial concerned.We will justify, in the final report,
any exclusion of a potentially eligible trial from the review.
Data extraction and management
Two review authors (CH and PL) will independently extract data.
We will summarise data using a pre designed data extraction form.
We will pilot the data extraction tool. Data from trials published
in duplicate will be included only once. One review author will
extract the data (CH) and a second (PL) will check the data for
accuracy. Any discrepancy will be resolved by discussion or in
consultation with a third review author (MVD).
We will extract the following data:
• Source (study ID);
• Eligibility (confirm eligibility for review);
• Characteristics of the trial (date of study, setting, location of
care, country, source of funding);
• Methods (study design, sequence generation, allocation
sequence concealment, blinding, other concerns about bias);
• Participants (number, diagnostic criteria, age, sex, co
morbidities, class of wound);
• Intervention (type of topical antibiotic, delivery vehicle,
dose, frequency of application, co interventions);
• Comparative intervention (placebo ointment, alternative
antibiotic ointment, no treatment control);
• For each outcome of interest: outcome definition, unit of
measurement, for scales upper and lower limit;
• Primary outcomes (definition of surgical site infection, unit
of measurement);
• Secondary outcomes (outcome definition and unit of
measurement);
• Results (number of participants allocated to each
intervention group, sample size, missing participants, summary
data - e.g. 2x2 data for dichotomous data, means and standard
deviations for continuous data, estimate of effect with confidence
intervals and P value, subgroup analysis).
• Key conclusions of study authors.
Assessment of risk of bias in included studies
Two review authors (CH and PL) will independently assess each
included study. Assessment will be undertaken using theCochrane
Collaboration’s tool for assessing risk of bias (Higgins 2011). The
’Risk of bias’ tool considers the domains of:
• sequence generation;
• allocation concealment;
• blinding of participants and personnel;
• blinding of outcome assessment;
• incomplete outcome data;
• freedom from selective reporting; and
• other potential bias.
We acknowledge that there is no accepted definition of what con-
stitutes a trial at high risk of bias, therefore we will set a threshold
so that trials assessed as at risk for any one of the following essential
elements of risk of bias - random number generation, allocation
concealment and assessor blinding - will be considered to be at
high risk of bias. Also, if missing outcome data are unequally dis-
tributed over the intervention arms we will discuss this, consider
the study at high risk of bias, and perform intention to treat anal-
ysis.
We will complete a ’Risk of bias’ table for each eligible study. We
will combine these data into a ’Risk of bias’ summary figure.
Measures of treatment effect
The primary outcome is dichotomous (wound infection or no
wound infection) and will be measured using risk ratio as the ef-
fect measure, with 95% confidence interval. We will use mean
difference with standard deviation and 95% confidence interval to
analyse continuous variables (patient satisfaction) using the same
scales. Where different scales are used to assess continuous out-
comes, we will use standardised mean difference with standard de-
viation in the analysis (Deeks 2011). Time-to-healing is a form of
time-to-event data, more correctly analysed using survival meth-
ods which can account for censoring (i.e. just for the time that
people were observed, so it takes account of when they dropped
out); it is inappropriate to report and analyse time-to-wound heal-
ing as if it were a continuous variable unless everyone healed and
there was no loss to follow-up.
Unit of analysis issues
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Theunit of analysis in trials ismost likely to be the patient recruited
into the trial. It is possible that cluster randomised trial designs
will be encountered, for example randomisation by surgeon, or
by operating list, or by general practice surgery or hospital. We
will analyse such trials based on allocation, using summary values
for each cluster, allowing the clusters to become the individuals
and analyse them as such. We will use analysis from the trials
that adjust for clustering. If there are trials that do not adjust for
clustering, we will attempt to adjust the analysis for correlation.
This may be done through a number of methods, ideally based on
a direct estimate of the required effect measure as stated in Deeks
2011. We will use the generic inverse variance method in Review
Manager 5 (RevMan 2014) to pool data from cluster randomised
trials (Deeks 2011).
If there are three arms in a study,where twoof the arms are clinically
similar for the purposes of the review, we will combine arms to
create a single pair-wise comparison. Where we cannot combine
arms and we include multiple arms in the same analysis, we will
divide the control group(s) between the two arms for the purpose
of comparison.
In order to avoid unit of analysis error when measurement occurs
at multiple time points, we will only pool data from one time
point that is closest to the other included studies.
Dealing with missing data
If the results of a RCT have been published, but information on
the outcome of interest is not reported, we will attempt, whenever
possible, to contact the trial authors for themissing information. If
continuous data are not presented as mean and standard deviation,
we will attempt, whenever possible, to contact the trial authors for
the information in this format. If the data are not available, we will
attempt to impute the missing standard deviation by borrowing
from similar studies or we will calculate the standard deviation
from P values, t values, confidence intervals or standard errors,
whichever is available.We will follow themethods described in the
Cochrane Handbook for Systematic Reviews of Interventions (Deeks
2011). In the completed review, we will report all efforts made to
obtain additional information.
Excluding participants from the analysis after randomisation, or
ignoring participants lost to follow-up can, in effect, undo the pro-
cess of randomisation, and thus potentially introduce bias into the
trial. Therefore, where possible, all analyses will be by intention-
to-treat (Hollis 1999). If participants were allocated to one in-
tervention (for example, antibiotic ointment), but after randomi-
sation underwent a different intervention (for example, placebo
ointment), they will be analysed according to their randomisation
allocation.
If the results for dichotomous variables are not reported in some
participants, we will base our analysis on both a worst possible out-
come (for example, wound infection occurred in all non reported
cases), and a best possible outcome (for example, wound infection
did not occur in any non reported cases). Where participants are
excluded from analysis without good cause we will conduct a sen-
sitivity analysis to determine any effect of attrition bias.
Assessment of heterogeneity
We will explore the presence or absence of heterogeneity using vi-
sual inspection of forest plots. If there is no apparent face value het-
erogeneity (e.g. clearly different populations or types of wounds,
different category of control group) we will perform a Chi2 test
with significance set at P value 0.10. We will also calculate the I2
statistic (Deeks 2011). This explores the proportion of variability
caused by heterogeneity rather than by chance. Thresholds for the
interpretation of the I2 statistic can be misleading. A rough guide
to interpretation will be:
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity; and
• 75% to 100%: considerable heterogeneity.
When interpreting and exploring the I2 statistic, we will take fac-
tors such as clinical and methodological heterogeneity - in partic-
ular the placebo treatment used - along with whether the hetero-
geneity is in the magnitude of effect or in the direction of effect,
into account, particularly where ranges overlap (Deeks 2011). We
will explore this further in subgroup analyses. If heterogeneity is
very high (> 75%), we will not pool these studies; we will explore
the impact of heterogeneity on the overall outcome with a sensi-
tivity analysis (see Sensitivity analysis).
Assessment of reporting biases
We will compare the reported outcomes with those stated in the
published protocol of the studies, if available, or in the methods
sectionof the published report, and also those listed in clinical trials
registries as both primary and secondary outcomes (for example
http://www.clinicaltrials.gov/). If sufficient studies are identified
(a minimum of 10), we will assess the risk of publication bias by
creating a funnel plot using software within Review Manager 5
(RevMan 2014), using visual inspection and statistical tests for
asymmetry.
Data synthesis
One review author (CH) will enter quantitative data into Review
Manager 5 (RevMan 2014), and a second (PL) will check the data.
Wewill calculate summary estimates of treatment effect (with 95%
confidence interval) for each outcome and every comparison. For
continuous outcomes, we will present the pooled mean difference
with the standard deviation as a measure of the spread. For di-
chotomous outcomes, we will calculate the risk ratio as the effect
measure, with 95% confidence interval. We will also calculate the
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absolute risk difference, that will allow us to calculate the num-
ber needed to treat. We will meta-analyse the results of clinically
homogenous studies using Review Manager 5 (RevMan 2014).
We will conduct meta-analyses using a random-effects model. If
insufficient data are available for meta-analyses, we will present
a narrative synthesis of the outcome across the included studies.
We will present all results in ’Summary of findings’ tables, and
rate the quality of evidence using the GRADE system (see below)
(Schünemann 2011a).
Subgroup analysis and investigation of heterogeneity
If there are sufficient trials of adequate size it may be possible to
conduct subgroup analyses.
We plan to conduct subgroup analyses for:
• class 1 versus class 2 versus class 3 wounds;
• dermatological versus general surgery;
• class of antibiotic used;
• single application versus multiple applications; and
• no treatment control versus placebo ointment control.
We will look at results and heterogeneity within subgroups. If
there are only two subgroups we will investigate if the confidence
intervals overlap, and we will perform statistical tests of subgroup
comparison.
Sensitivity analysis
We will perform a sensitivity analysis to assess the impact of het-
erogeneity on the overall estimate of effect by first pooling all stud-
ies, and subsequently removing the outlier studies that seem to be
contributing to the statistical heterogeneity. We will also perform
sensitivity analysis to assess the impact of risk of bias on the overall
effect measure. We will compare the outcomes of these analyses
and describe the implications for the conclusion of the review. We
plan to remove studies at high risk of bias in order to assess the
effect of this on the result.
Summary of findings tables
We will present the main results of the review in ’Summary of
findings’ tables. These tables present key information concerning
the quality of the evidence, the magnitude of the effects of the
interventions examined, and the sum of the available data for the
main outcomes (Schünemann 2011a). The ’Summary of findings’
tables also include an overall grading of the evidence related to
each of the main outcomes using the GRADE (Grades of Recom-
mendation, Assessment, Development and Evaluation) approach.
The GRADE approach defines the quality of a body of evidence as
the extent to which one can be confident that an estimate of effect
or association is close to the true quantity of specific interest. The
quality of a body of evidence involves consideration of within-
trial risk of bias (methodological quality), directness of evidence,
heterogeneity, precision of effect estimates and risk of publication
bias (Schünemann 2011b).
We plan to present the following outcomes in the ’Summary of
findings’ tables:
• superficial surgical site infection;
• adverse events;
• time-to-complete wound healing, or proportion of wounds
healed during the trial period.
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A D D I T I O N A L T A B L E S
Table 1. Table 1: Wound classification
Preoperative classification Wound type Maximum expected postoper-
ative infection rate
Example of wound
Class 1/Clean Noncontaminated wound 5% Sterile minor skin excision
Class 2/Clean Contaminated Operative wound in respiratory,
alimentary, genitourinary tract,
minor break in aseptic tech-
nique
10% Biliary tract, appendix, vagina,
oropharynx
Class 3/Contaminated Open, fresh, accidental wound,
acute nonpurulent inflamma-
tion, gross spillage from gas-
20% to 30% Open cardiac massage, gross
spillage from gastrointestinal
tract
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Table 1. Table 1: Wound classification (Continued)
trointestinal tract, major break
in aseptic technique
Class 4/ Dirty-Infected Purulent in-
flammation, Gross contamina-
tion with foreign bodies, pene-
trating trauma> 4 hours old, de-
vitalised tissue
30% to 40% Old traumatic wound, abscess
Table 2. Table 2: Topical antibiotics
Ointment Trade name, avail-
ability
Mode of activity Range of activity Main use Side effects/ad-
ditional considera-
tions













Bacitracin Ingredient of triple
antibiotic ointment
Interferes with bac-








Polymixin B Available singly,
combined with bac-

















alone, or as ingredi-
ent of triple antibi-
otic ointment
Interferes with bac-
terial cell wall syn-
thesis
Aerobic gram +ve














Range of gram +ve








Erythromycin Eryacne Inhibitor of bacte-
rial protein synthe-
sis






Wide range of gram
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1 Antibiotic Prophylaxis/
2 exp Anti-Bacterial Agents/
3 Ointments/
4 Skin Cream/
5 exp Administration, Topical/
6 1 or 2
7 5 and 6
8 (topical adj5 antibiotic*).tw.
9 (mupirocin or bactroban or bacitracin or polymixin B or neomycin or erythromycin or chloramphenicol or chlormycetin or chlorsig
or neosporin).tw.
10 (antibiotic* adj5 (foam* or tincture* or gel or gels or solution* or lotion* or cream*)).tw.
11 (antibiotic* adj5 (powder* or liquid* or drop* or spray* or paste* or ointment*)).tw.
12 ((antibiotic* or impregnat*) adj5 dressing*).tw.
13 3 or 4 or 7 or 8 or 9 or 10 or 11 or 12
14 Surgical Wound Infection/
15 Surgical Wound Dehiscence/
16 (surg* adj5 infect*).tw.
17 (surg* adj5 wound*).tw.
18 (surg* adj5 site*).tw.
19 (surg* adj5 incision*).tw.
20 (surg* adj5 dehisc*).tw.
21 (wound* adj5 dehisc*).tw.
22 (wound* adj5 infect*).tw.
23 (wound* adj5 disrupt*).tw.
24 wound complication*.tw.
25 or/14-24
26 13 and 25
27 randomized controlled trial.pt.
28 controlled clinical trial.pt.
29 randomi?ed.ab.
30 placebo.ab.




35 exp animals/ not humans.sh.
36 34 not 35
37 26 and 36
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Appendix 2. EMBASE search strategy
1 antibiotic prophylaxis/
2 exp antibiotic agent/
3 exp ointment/
4 skin cream/
5 exp topical drug administration/
6 1 or 2
7 5 and 6
8 (topical adj5 antibiotic*).tw.
9 (mupirocin or bactroban or bacitracin or polymixin B or neomycin or erythromycin or chloramphenicol or chlormycetin or chlorsig
or neosporin).tw.
10 (antibiotic* adj5 (foam* or tincture* or gel or gels or solution* or lotion* or cream*)).tw.
11 (antibiotic* adj5 (powder* or liquid* or drop* or spray* or paste* or ointment*)).tw.
12 ((antibiotic* or impregnat*) adj5 dressing*).tw.
13 3 or 4 or 7 or 8 or 9 or 10 or 11 or 12
14 surgical infection/
15 wound dehiscence/
16 (surg* adj5 infect*).tw.
17 (surg* adj5 wound*).tw.
18 (surg* adj5 site*).tw.
19 (surg* adj5 incision*).tw.
20 (surg* adj5 dehisc*).tw.
21 (wound* adj5 dehisc*).tw.
22 (wound* adj5 infect*).tw.
23 (wound* adj5 disrupt*).tw.
24 wound complication*.tw.
25 or/14-24
26 13 and 25




31 (random$ or factorial$ or crossover$ or cross over$ or cross-over$ or placebo$ or assign$ or allocat$ or volunteer$).ti,ab.
32 (doubl$ adj blind$).ti,ab.
33 (singl$ adj blind$).ti,ab.
34 or/27-33
35 exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
36 human/ or human cell/
37 and/35-36
38 35 not 37
39 34 not 38
40 26 and 39
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Appendix 3. CINAHL search strategy
S39 S26 AND S38
S38 S27 or S28 or S29 or S30 or S31 or S32 or S33 or S34 or S35 or S36 or S37
S37 MH “Quantitative Studies”
S36 TI placebo* or AB placebo*
S35 MH “Placebos”
S34 TI random* allocat* or AB random* allocat*
S33 MH “Random Assignment”
S32 TI randomi?ed control* trial* or AB randomi?ed control* trial*
S31 AB ( singl* or doubl* or trebl* or tripl* ) and AB ( blind* or mask* )
S30 TI ( singl* or doubl* or trebl* or tripl* ) and TI ( blind* or mask* )
S29 TI clinic* N1 trial* or AB clinic* N1 trial*
S28 PT Clinical trial
S27 MH “Clinical Trials+”
S26 S13 AND S25
S25 S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24
S24 TI wound N1 complication* OR AB wound N1 complication*
S23 TI wound* N5 disrupt* OR AB wound* N5 disrupt*
S22 TI wound* N5 infect* OR AB wound* N5 infect*
S21 TI wound* N5 dehisc* OR AB wound* N5 dehisc*
S20 TI surg* N5 dehisc* OR AB surg* N5 dehisc*
S19 TI surg* N5 incision* OR AB surg* N5 incision*
S18 TI surg* N5 site* OR AB surg* N5 site*
S17 TI surg* N5 wound* OR AB surg* N5 wound*
S16 TI surg* N5 infect* OR AB surg* N5 infect*
S15 (MH “Surgical Wound Dehiscence”)
S14 (MH “Surgical Wound Infection”)
S13 S3 OR S4 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12
S12 TI ( (antibiotic* or impregnat*) N5 dressing* ) OR AB ( (antibiotic* or impregnat*) N5 dressing* )
S11 TI ( antibiotic* N5 (powder* or liquid* or drop* or spray* or paste* or ointment*) ) OR AB ( antibiotic* N5 (powder* or liquid*
or drop* or spray* or paste* or ointment*) )
S10 TI ( antibiotic* N5 (foam* or tincture* or gel or gels or solution* or lotion* or cream*) ) OR AB ( antibiotic* N5 (foam* or
tincture* or gel or gels or solution* or lotion* or cream*) )
S9 TI ( mupirocin or bactroban or bacitracin or “polymixin B” or neomycin or erythromycin or chloramphenicol or chlormycetin or
chlorsig or neosporin )ORAB (mupirocin or bactrobanor bacitracin or “polymixinB” or neomycin or erythromycin or chloramphenicol
or chlormycetin or chlorsig or neosporin )
S8 TI topical N5 antibiotic* OR AB topical N5 antibiotic*
S7 S5 AND S6
S6 S1 OR S2
S5 (MH “Administration, Topical+”)
S4 (MH “Creams”) OR (MH “Powders”)
S3 (MH “Ointments”)
S2 (MH “Antibiotics+”)
S1 (MH “Antibiotic Prophylaxis”)
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